EGFR and PI3K pathway signaling has also been implicated in the adaptive resistance of KRAS-mutant and BRAF-mutant colorectal cancer (CRC) to RAS–MAPK (mitogen-activated protein kinase) pathway intervention. This evidence concerns the gene KRAS and colorectal carcinoma.